Items in BOLD are required.
Page 2
Page 3

Physician Focus on Parkinson's

Issue 15 (Fall 2010) - Quarterly CME Newsletter on Parkinson's Disease

To receive CME credit for this activity, please complete the post-test and evaluation below.  Once submitted, a certificate will be issued within two weeks to the email address provided.

to view Issue 15 online.  You may also view the Patient Education Tool online here.

If you have any questions, please contact intellyst® Medical Education at 720-748-8800.

Target Audience
Neurologists, NPs and PAs specializing in neurology.

Statement of Need

Parkinson’s disease (PD) is the second most common neurodegenerative disease. The mean age of onset is 61 years, but may begin as early as age 40 or less. It affects an estimated half million to one million Americans. That number is expected to double in the next 25 years as the population ages and as treatments for other diseases prolong the survival of aging adults. PD is classified as a movement disorder, because its most prominent symptoms are tremor, rigidity, slowed movements, and postural instability. However, PD also includes a wide range of non-motor symptoms, including depression, anxiety, sleep disorder, and autonomic symptoms, and these may be at least as debilitating as motor symptoms for many patients.

Learning Objectives
At the conclusion of this activity, participants should be able to:
•    Discuss non-motor features of Parkinson’s disease and their impact on quality of life, including, anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders
•    Describe medications available for treatment of motor symptoms of Parkinson’s disease in early and fluctuating disease as well as their side effects
•    Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease modifying agents in Parkinson’s disease

Andrew Siderowf, MD (Case Study Contributor)
Gary VanderArk, MD (Independent Reviewer)
Richard Robinson (Medical Writer)

Accreditation Statement
intellyst® Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation
intellyst® Medical Education designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.